MCID: IRR002
MIFTS: 63

Irritable Bowel Syndrome

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 72 36 40 41 14 69 59
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9778
ICD10 32 K58 K58.9 K58.0
ICD9CM 34 564.1
MeSH 41 D043183
NCIt 46 C82343
KEGG 36 H01615
UMLS 69 C0022104

Summaries for Irritable Bowel Syndrome

MedlinePlus : 40 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to dyspepsia and celiac disease 1, and has symptoms including gastrointestinal gas, vomiting following gastrointestinal surgery and nausea and vomiting. An important gene associated with Irritable Bowel Syndrome is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian rythm related genes. The drugs Loperamide and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

PubMed Health : 59
About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 72 Irritable bowel syndrome (IBS) is a group of symptoms—including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 dyspepsia 31.2 CCK HTR3A SLC6A4 TRPV1
2 celiac disease 1 30.5 CCK IL10 TGM2 TNF
3 chronic fatigue syndrome 30.4 CRH IL10 SLC6A4 TNF
4 anxiety 30.3 CCK CRH CRHR1 HTR3A SLC6A4 TPH1
5 generalized anxiety disorder 30.3 CRHR1 HTR3A SLC6A4 TPH1
6 postcholecystectomy syndrome 30.1 CCK MLN
7 constipation 29.9 CCK HTR3A HTR4 MLN SLC6A4 TAC1
8 panic disorder 29.9 CCK CRH CRHR1 HTR3A SLC6A4 TPH1
9 bulimia nervosa 1 29.9 CCK HTR3A HTR7 SLC6A4
10 functional diarrhea 29.7 HTR3A HTR4 HTR7 TAC1
11 cystitis 29.7 TAC1 TNF TRPV1
12 rhinitis 29.4 TLR9 TRPV1 VIP
13 somatoform disorder 29.4 TAC1 TPH1 TRPV1
14 inflammatory bowel disease 29.2 CHGA IL10 TAC1 TLR9 TNF VIP
15 vasomotor rhinitis 29.2 TAC1 TLR9 VIP
16 gastrointestinal system disease 28.6 CCK CRH HTR4 IL10 MLN TLR9
17 migraine with or without aura 1 28.3 HTR3A HTR7 SLC6A4 TAC1 TNF TPH1
18 asthma 28.2 IL10 TAC1 TLR9 TNF TRPV1 VIP
19 isobutyryl-coa dehydrogenase deficiency 11.7
20 gastrointestinal defects and immunodeficiency syndrome 11.5
21 diarrhea 11.4
22 interstitial cystitis 11.4
23 fecal incontinence 11.3
24 acquired fructose intolerance 11.2
25 colonic disease 10.9
26 hereditary alpha tryptasemia syndrome 10.9
27 postural orthostatic tachycardia syndrome 10.9
28 punctate inner choroidopathy 10.6 IL10 TNF
29 tropical endomyocardial fibrosis 10.6 IL10 TNF
30 social phobia 10.5 CCK HTR3A SLC6A4
31 episodic pain syndrome, familial, 1 10.5
32 pylorospasm 10.5 HTR4 MLN
33 microscopic polyangiitis 10.5 IL10 TNF
34 multifocal choroiditis 10.5 IL10 TNF
35 early-onset schizophrenia 10.5 HTR3A SLC6A4 TNF
36 tungiasis 10.4 IL10 TNF
37 endomyocardial fibrosis 10.4 IL10 TNF
38 colitis 10.4
39 gastroparesis 10.4 CCK HTR3A MLN
40 transient hypogammaglobulinemia 10.4 IL10 TNF
41 allergic hypersensitivity disease 10.4
42 bulimia nervosa 2 10.4 CCK CRH SLC6A4
43 pancreas disease 10.4 CCK TNF TRPV1
44 mucositis 10.4
45 gallbladder disease 10.4 CCK IL10 MLN
46 mitral valve disease 10.4 IL10 SLC6A4 TPH1
47 choroiditis 10.3 IL10 TNF
48 lactose intolerance 10.3
49 microscopic colitis 10.3
50 chronic pulmonary heart disease 10.3 HTR7 SLC6A4 TNF

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 26)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Generalized Anxiety Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:



Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:


gastrointestinal gas, vomiting following gastrointestinal surgery, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

GenomeRNAi Phenotypes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A MLN SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 VIP TNF TPH1 TRPV1 TAC1 TGM2
2 homeostasis/metabolism MP:0005376 10.22 VIP TLR9 TNF TPH1 TRPV1 TGM2
3 endocrine/exocrine gland MP:0005379 10.14 VIP TNF SLC6A4 TGM2 CRH IL10
4 cardiovascular system MP:0005385 10.13 VIP TGM2 TNF TPH1 SLC6A4 TAC1
5 growth/size/body region MP:0005378 10.11 TGM2 TNF TPH1 SLC6A4 TRPV1 CRH
6 nervous system MP:0003631 9.93 TGM2 TNF SLC6A4 TRPV1 CRH IL10
7 integument MP:0010771 9.91 TNF TPH1 SLC6A4 TAC1 TRPV1 IL10
8 no phenotypic analysis MP:0003012 9.56 TGM2 TNF TRPV1 IL10 CRH CRHR1
9 renal/urinary system MP:0005367 9.23 TGM2 TLR9 TAC1 TRPV1 CRH HTR3A

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMedHealth treatment related to Irritable Bowel Syndrome: 59

There are a lot of different opinions about what can help relieve irritable bowel syndrome. Common recommendations include eating or avoiding certain foods and getting exercise. But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps.For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while.There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include:Fiber supplements, for instance made from psylliumPeppermint oilProbioticsAnti-cramping medicationsMedications for constipation or diarrheaVarious medications, such as antibiotics or antidepressantsPsychological treatments, such as stress management or hypnosisBecause medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loperamide Approved Phase 4,Phase 3,Phase 2 53179-11-6 3955
2
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
6
Perphenazine Approved Phase 4 58-39-9 4748
7
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
8 Ramosetron Approved, Investigational Phase 4,Phase 3,Phase 2 132036-88-5
9
Norepinephrine Approved Phase 4 51-41-2 439260
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Curcumin Approved, Investigational Phase 4,Phase 2 458-37-7 969516
12
Pantoprazole Approved Phase 4 102625-70-7 4679
13
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
14
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
15
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
16
Metronidazole Approved Phase 4 443-48-1 4173
17
Lubiprostone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136790-76-6 656719
18
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
19 Ebastine Approved, Investigational Phase 4 90729-43-4 3191
20
Trimebutine Approved Phase 4,Phase 2,Phase 3 39133-31-8
21
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
22
Pancrelipase Approved, Investigational Phase 4 53608-75-6
23
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
24
Alverine Approved, Investigational Phase 4 150-59-4 3678
25
Eluxadoline Approved, Investigational Phase 4,Phase 2 864821-90-9
26 Simethicone Approved Phase 4,Phase 1
27
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
29
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
30
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 77-92-9 311
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 1406-16-2
33
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 1 67-97-0 10883523 5280795 6221
34 Mosapride Investigational Phase 4,Phase 3,Phase 2 112885-41-3
35 Tiropramide Investigational Phase 4 55837-29-1 42262
36
Genistein Investigational Phase 4 446-72-0 5280961
37
Maleic acid Experimental Phase 4 110-16-7 444266
38 Fenoverine Investigational Phase 4 37561-27-6
39 rifamycin SV Phase 4,Phase 3,Phase 2
40
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
41 Analgesics Phase 4,Phase 3,Phase 2
42 calcium channel blockers Phase 4,Phase 2
43 Cathartics Phase 4,Phase 3,Phase 2,Phase 1
44 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
45 Rifamycins Phase 4,Phase 3,Phase 2
46 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Serotonin Agents Phase 4,Phase 3,Phase 2
48 Serotonin Antagonists Phase 4,Phase 3,Phase 2
49 Serotonin Uptake Inhibitors Phase 4,Phase 2
50 Muscarinic Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 662)

# Name Status NCT ID Phase Drugs
1 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
2 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
3 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
4 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
5 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
6 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
7 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
8 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
9 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
10 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
11 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
12 Effect of Ramosetron on Bowel Motility After Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
13 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
14 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
15 Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
16 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Completed NCT00401258 Phase 4 duloxetine
17 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
18 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
19 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
20 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome Completed NCT01331213 Phase 4 Pregabalin;Placebo
21 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
22 Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS) Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
23 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Completed NCT02959983 Phase 4 Eluxadoline;Placebo
24 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4 Ramosetron;Placebo
25 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
26 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
27 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4 Mesalazine;Placebo
28 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
29 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
30 Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study Completed NCT02077699 Phase 4
31 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
32 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
33 Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
34 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4 Colesevelam
35 Comparative Efficacy and Safety of Fenoverine Completed NCT01507922 Phase 4 Fenoverine;Timebutine
36 Multi-strain Probiotic in the Management of IBS-D Completed NCT03251625 Phase 4 Probiotic Formula Capsule
37 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
38 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
39 EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
40 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4 Ondansetron;Placebo
41 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
42 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4 alosetron
43 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Completed NCT01667627 Phase 4
44 Mode of Action of Moviprep Completed NCT01622972 Phase 4 Polyethyleneglycol
45 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
46 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
47 Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption Completed NCT01763281 Phase 4 CRH;Placebo
48 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
49 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
50 Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children Completed NCT01595932 Phase 4

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

38
Colon, Testes, Brain, Small Intestine, Kidney, Liver, Heart

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 1012)
# Title Authors Year
1
Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. ( 29408906 )
2018
2
Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: an Acttion Systemic Review. ( 29412183 )
2018
3
Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome. ( 29402137 )
2018
4
Effect of<i>Lactobacillus rhamnosus</i>GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. ( 29391756 )
2018
5
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. ( 29445178 )
2018
6
Food consumption and dietary intakes in 36,448 adults and their association with irritable bowel syndrome: Nutrinet-SantAc study. ( 29399039 )
2018
7
The prevalence of celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome of China, a prospective, controlled, cohort study. ( 29451364 )
2018
8
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. ( 29446765 )
2018
9
Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. ( 29372261 )
2018
10
Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. ( 29408290 )
2018
11
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
12
The Role of Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review. ( 29413008 )
2018
13
G protein beta 3(<i>GNI^3</i>) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies. ( 29416810 )
2018
14
Prevalence of Fructose Malabsorption in Patients With Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth. ( 29433301 )
2018
15
The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome. ( 29447026 )
2018
16
Sensitive bowel syndrome better than irritable bowel syndrome. ( 29426620 )
2018
17
Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. ( 29434653 )
2018
18
Advancements in drug development for diarrhea-predominant irritable bowel syndrome. ( 29451407 )
2018
19
Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. ( 28886490 )
2017
20
Prevalence of lactose intolerance in patients with diarrhea-predominant irritable bowel syndrome: data from a tertiary center in southern China. ( 29157302 )
2017
21
Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. ( 28092305 )
2017
22
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. ( 28936910 )
2017
23
Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: a Systematic Review and Meta-analysis. ( 28069350 )
2017
24
Intestinal microbiome-gut-brain axis and irritable bowel syndrome. ( 28887729 )
2017
25
The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. ( 28932272 )
2017
26
Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome. ( 28059627 )
2017
27
Antinociceptive Effect of Ghrelin in a Rat Model of Irritable Bowel Syndrome Involves TRPV1/Opioid Systems. ( 28930716 )
2017
28
Comparison of Resilience and Psychological Wellbeing in Women with Irritable Bowel Syndrome and Normal Women. ( 28883772 )
2017
29
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017
30
Is-it possible to distinguish irritable bowel syndrome with constipation from functional constipation? ( 28066860 )
2017
31
Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome - a population based study. ( 28521729 )
2017
32
Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. ( 28894393 )
2017
33
Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? ( 28880445 )
2017
34
Effect of retrograde colonic electrical stimulation on colonic transit and stress-induced visceral hypersensitivity in rats with irritable bowel syndrome. ( 28942833 )
2017
35
Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome. ( 29390477 )
2017
36
Irritable bowel syndrome and endometriosis: New insights for old diseases. ( 29396128 )
2017
37
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. ( 28932270 )
2017
38
Irritable Bowel Syndrome-Like Symptoms Following Fecal Microbiota Transplantation: A Possible Donor-Dependent Complication. ( 28050036 )
2017
39
The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals. ( 27750262 )
2017
40
Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa from Patients with Irritable Bowel Syndrome. ( 28246611 )
2017
41
Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. ( 27862119 )
2017
42
Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome. ( 28054654 )
2017
43
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. ( 28083815 )
2017
44
Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. ( 28074514 )
2017
45
Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply. ( 28880440 )
2017
46
Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology and management. ( 28901578 )
2017
47
Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. ( 28884838 )
2017
48
Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. ( 27869798 )
2017
49
Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. ( 28711627 )
2017
50
Blastocystis and irritable bowel syndrome: Frequency and subtypes from Iranian patients. ( 28087441 )
2017

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

Pathways related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 CCK CRH CRHR1 HTR4 HTR7 MLN
3 11.85 HTR3A IL10 SLC6A4 TAC1 TNF TPH1
4 11.82 CRH CRHR1 HTR4 HTR7 VIP
5
Show member pathways
11.72 IL10 TLR9 TNF
6 11.54 IL10 TLR9 TNF
7 11.49 HTR3A HTR3E HTR4 HTR7 SLC6A4 TPH1
8 11.47 IL10 TLR9 TNF
9 11.23 IL10 TLR9 TNF
10 11.04 IL10 TLR9 TNF
11 10.47 HTR3A HTR4 HTR7 SLC6A4 TPH1
12 10.28 CCK VIP
13 10.25 CRH CRHR1

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 CCK CHGA CRH IL10 MLN TAC1
2 neuronal cell body GO:0043025 9.35 CCK CRH HTR3A TAC1 TRPV1
3 intrinsic component of plasma membrane GO:0031226 8.8 CRHR1 TGM2 TRPV1
4 plasma membrane GO:0005886 10.03 CRHR1 HTR3A HTR3E HTR4 HTR7 OCLN

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.97 CCK CRH CRHR1 HTR4 HTR7 MLN
2 regulation of receptor activity GO:0010469 9.91 CCK IL10 MLN TNF VIP
3 defense response to bacterium GO:0042742 9.8 CHGA IL10 TLR9 TNF
4 response to organic substance GO:0010033 9.74 IL10 SLC6A4 TNF
5 circadian rhythm GO:0007623 9.72 HTR7 SLC6A4 TPH1
6 negative regulation of growth of symbiont in host GO:0044130 9.58 IL10 TNF
7 response to molecule of bacterial origin GO:0002237 9.56 IL10 TLR9
8 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 IL10 TNF
9 parturition GO:0007567 9.52 CRH CRHR1
10 negative regulation of interleukin-6 production GO:0032715 9.5 IL10 TLR9 TNF
11 endothelial cell apoptotic process GO:0072577 9.48 IL10 TNF
12 negative regulation of cytokine secretion involved in immune response GO:0002740 9.46 IL10 TNF
13 negative regulation of interleukin-8 production GO:0032717 9.43 IL10 TLR9
14 inflammatory response GO:0006954 9.43 CRH IL10 TAC1 TLR9 TNF TRPV1
15 receptor biosynthetic process GO:0032800 9.4 IL10 TNF
16 response to pain GO:0048265 9.33 CRH TAC1 TRPV1
17 positive regulation of corticosterone secretion GO:2000854 9.26 CRH TAC1
18 chemical synaptic transmission GO:0007268 9.1 CRH HTR3A HTR3E HTR4 HTR7 TAC1

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.55 CRHR1 HTR3A HTR3E TLR9 TRPV1
2 extracellular ligand-gated ion channel activity GO:0005230 9.43 HTR3A HTR3E TRPV1
3 serotonin binding GO:0051378 9.37 HTR3A HTR7
4 serotonin-gated cation-selective channel activity GO:0022850 9.32 HTR3A HTR3E
5 neuropeptide hormone activity GO:0005184 9.13 CCK CRH VIP
6 hormone activity GO:0005179 8.92 CCK CRH MLN VIP

Sources for Irritable Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....